China National Biotech Group
Beijing
China
18 articles about China National Biotech Group
-
Croma Establishes New Joint Venture in China
9/15/2020
Austria-based medical aesthetic products’ manufacturer Croma-Pharma GmbH establishes new Joint Venture with China National Biotech Group Company Ltd. to market its premium Hyaluronic Acid Filler Princess® VOLUME and various additional aesthetic products of Croma in China and Hong Kong.
-
China National Biotech Group's Japanese Encephalitis Vaccine Prequalified by World Health Organization
10/9/2013
-
Hua Han Bio-Pharma and China National Biotech Group Announce JV
4/23/2013
-
China National Biotech Group's $1.5 Billion IPO is Rumored Again
1/15/2013
-
China National Biotech Group May Soon Sell Vaccine to International Aid Groups
10/5/2012
-
Week in Review: China National Biotech Group Plans $1.6 Billion Hong Kong IPO
9/10/2012
-
China National Biotech Group Approved for $1.6 Billion Hong Kong IPO
9/6/2012
-
China National Biotech Group Institute Buys Vaccine Conjugate Technology From FinaBio
8/21/2012
-
China National Biotech Group to Raise $1.6 Billion in Hong Kong IPO
5/18/2012
-
Aeras and China National Biotech Group Partner on TB Vaccine
1/10/2012
-
The Week in Review: China National Biotech Group Schedules $2 Billion IPO in Hong Kong
11/14/2011
-
China National Biotech Group's Hong Kong IPO to Raise Up to $2 Billion
11/9/2011
-
China National Biotech Group to IPO on the Hong Kong Exchange
11/7/2011
-
Immunobiology Limited (ImmBio) Strikes China Deal with China National Biotech Group Unit for TB Vaccine
11/4/2011
-
Aeras and China National Biotech Group Sign MOU for TB Vaccine
7/26/2011
-
Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
7/26/2011
-
China National Biotech Group Given Go-Ahead to Test HFMD Vaccine
12/28/2010
-
China National Biotech Group to Invest Over $263 Million in Diagnostic Reagent Production Base in Jilin
8/13/2007